Hologic to buy Focal Therapeutics

2018 07 31 22 13 5219 Hologic Rsna 2017 400

Women's imaging firm Hologic is planning to acquire Focal Therapeutics, the developer of an implantable 3D marker to mark tumor excision sites during lumpectomy procedures.

Hologic plans to pay $125 million for the privately held company, which it will add to its Breast Health product portfolio. Focal Therapeutics generated about $16 million in revenue over the past 12 months.

Focal Therapeutics makes BioZorb, a 3D marker placed by surgeons to mark excision sites for monitoring and future treatments. BioZorb has an open design that allows for tissue in-growth during the healing process, according to Hologic.

Page 1 of 569
Next Page